An Open-Labeled, Multicenter Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
Esophagus | Other Digestive Organ
What is the purpose of this trial?
To demonstrate the antitumor activity as assessed by the rate of progression free survival at three months of the sanofi-aventis product cabazitaxel 25mg/m2 IV over 1 hour every 3 weeks in subjects with previously treated metastatic gastroesophageal adenocarcinoma who are either taxane naïve, or taxane previously treated
Click here for detailed information about who can participate in this trial.
- Weill Medical College of Cornell University
- Last Updated:
- Study HIC#: